scispace - formally typeset
D

David E. Shaw

Researcher at D. E. Shaw Research

Publications -  326
Citations -  50142

David E. Shaw is an academic researcher from D. E. Shaw Research. The author has contributed to research in topics: Massively parallel & G protein-coupled receptor. The author has an hindex of 88, co-authored 298 publications receiving 42616 citations. Previous affiliations of David E. Shaw include Protein Sciences & Genentech.

Papers
More filters
Patent

Method and system for the electronic negotiation and execution of equity block trades for institutional investors

TL;DR: In this paper, the authors present a system for electronic negotiation and execution of block-size trades in financial instruments on behalf of institutional investors, and in particular, a system and method for the anonymous execution of equity block trades for institutional investors.
Journal ArticleDOI

A dynamically coupled allosteric network underlies binding cooperativity in Src kinase

TL;DR: An allosteric network of dynamically coupled amino acids in Src kinase that connects regulatory sites to the ATP- and substrate-binding sites is identified and establishes a potential conduit by which resistance mutations to ATP-competitive kinase inhibitors can affect their activity.
Journal ArticleDOI

Atomic-level simulation of current–voltage relationships in single-file ion channels

TL;DR: Using long, all-atom simulations enabled by special-purpose hardware, K+ permeation across the KV1.2/2.1 voltage-gated potassium channel is studied, suggesting that the direct simulation of permeation at the single-ion level can provide fundamental physiological insight into ion channel function.
Journal ArticleDOI

Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH2): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor Growth

TL;DR: The identification of biomarkers of angiogenesis that also exhibit this same U-shaped response should allow the translation of those biomarkers to the clinic, allowing them to be used to identify the active dose of ATN-161 in phase II studies.